1. Department of Clinical Pharmacology Research Lab, The First Affiliated Hospital of Soochow University, Suzhou 215006, China; 2. College of Pharmaceutical Sciences, Soochow University, Suzhou 215100, China
Abstract��Monoclonal antibody (mAb) drugs currently are an important field in drug development and playing a wide role in the treatment of autoimmune diseases and tumor. However, interindividual variability of therapeutic response and loss of response during treatment become serious problems in clinic, and the underlying mechanisms are believed to be closely related to drug exposure in patients and immunogenicity. Therapeutic drug monitoring (TDM) of mAb drugs has the potential to guide more effective dosing in individual patients and it has been proved to be helpful when making treatment decisions particularly for tumor necrosis factor inhibitors. This review is to summarize the pharmacokinetic profiles and exposure-response relationship of mAb drugs, so as to provide theoretical basis and research direction for the application of TDM in mAb drugs.
RODGERS K R, CHOU R C. Therapeutic monoclonal antibodies and derivatives:historical perspectives and future directions. Biotechnol Adv, 2016, 34(6):1149-1158.
[2]
HETLAND M L, CHRISTENSEN I J, TARP U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab:results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Rthritis Rheum, 2010, 62(1):22-32.
[3]
PAPAMICHAEL K, CHEIFETZ A S. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol, 2016, 7(4):289-300.
[4]
KEIZER R J, HUITEMA A D, SCHELLENS J H, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet, 2010, 49(8):493-507.
[5]
CVETKOVIC R S, SCOTT L J. Adalimumab:a review of its use in adult patients with rheumatoid arthritis. Bio Drugs, 2006, 20(5):293-311.
[6]
MAIER S, CHUNG C H, MORSE M, et al. A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions. Cancer Med, 2015, 4(1):36-42.
[7]
RIDKER P M, TARDIF J C, AMARENCO P, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med, 2017, 376(16):1517-1526.
[8]
OUDE MUNNINK T H, HENSTRA M J, SEGERINK L I, et al. Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease:translating TNF-alpha experience to oncology. Clin Pharmacol Ther, 2016, 99(4):419-431.
[9]
CHEN D Y, CHEN Y M, HSIEH T Y, et al. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up. Rheumatology(Oxford), 2016, 55(1):143-148.
[10]
CHEN D Y, CHEN Y M, TSAI W C, et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis, 2015, 74(3):e16.
[11]
POUW M F, KRIECKAERT C L, NURMOHAMED M T, et al. Key findings towards optimising adalimumab treatment:the concentration-effect curve. Ann Rheum Dis, 2015, 74(3):513-518.
[12]
FEUERSTEIN J D, NGUYEN G C, KUPFER S S, et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology, 2017, 153(3):827-834.
[13]
MITREV N, VANDE CASTEELE N, SEOW C H, et al. Review article:consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther, 2017, 46(11-12):1037-1053.
[14]
KARMIRIS K, PAINTAUD G, NOMAN M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology, 2009, 137(5):1628-1640.
[15]
ROBLIN X, RINAUDO M, DEL TEDESCO E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol, 2014, 109(8):1250-1256.
[16]
SANMARTI R, INCIARTE-MUNDO J, ESTRADA-ALARCON P, et al. Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study. Ann Rheum Dis, 2015, 74(8):e42.
[17]
VAN DEN BEMT B J, DEN BROEDER A A, WOLBINK G J, et al. The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis. Br J Clin Pharmacol, 2013, 76(6):939-945.
[18]
VOGELZANG E H, KNEEPKENS E L, NURMOHAMED M T, et al. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis, 2014, 73(12):2178-2182.
[19]
MARSMAN A F, KNEEPKENS E L, RUWAARD J, et al. Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients. Scand J Rheumatol, 2016, 45(4):331-334.
[20]
BERINSTEIN N L, GRILLO-LOPEZ A J, WHITE C A, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol, 1998, 9(9):995-1001.
[21]
YANG J, ZHAO H, GARNETT C, et al. The combination of exposure-response and case-control analyses in regulatory decision making. J Clin Pharmacol, 2013, 53(2):160-166.
[22]
ROZMAN S, GRABNAR I, NOVAKOVIC S, et al. Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. Br J Clin Pharmacol, 2017, 83(8):1782-1790.
[23]
BRUNO R, WASHINGTON C B, LU J F, et al. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol, 2005, 56(4):361-369.
[24]
CHEN S C, KAGEDAL M, GAO Y, et al. Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). Cancer Chemother Pharmacol, 2017, 80(6):1147-1159.
[25]
WANG Y, BOOTH B, RAHMAN A, et al. Toward greater insights on pharmacokinetics and exposure-response relationships for therapeutic biologics in oncology drug development. Clin Pharmacol Ther, 2017, 101(5):582-584.
2018, Vol. 53 
